IFP Advisors’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.13K | Hold |
24
| – | – | ﹤0.01% | 4207 |
|
|
2026
Q1 | $1.21K | Hold |
24
| – | – | ﹤0.01% | 4145 |
|
|
2025
Q4 | $786 | Hold |
24
| – | – | ﹤0.01% | 4147 |
|
|
2025
Q3 | $402 | Buy |
24
+1
| +4% | +$16 | ﹤0.01% | 4242 |
|
|
2025
Q2 | $374 | Sell |
23
-86
| -79% | -$1.27K | ﹤0.01% | 4503 |
|
|
2025
Q1 | $1.92K | Hold |
109
| – | – | ﹤0.01% | 3157 |
|
|
2024
Q4 | $2.77K | Sell |
109
-5
| -4% | -$147 | ﹤0.01% | 2986 |
|
|
2024
Q3 | $3.35K | Hold |
114
| – | – | ﹤0.01% | 2787 |
|
|
2024
Q2 | $2.68K | Hold |
114
| – | – | ﹤0.01% | 2752 |
|
|
2024
Q1 | $4.32K | Hold |
114
| – | – | ﹤0.01% | 2498 |
|
|
2023
Q4 | $2.45K | Sell |
114
-2,860
| -96% | -$39.4K | ﹤0.01% | 2628 |
|
|
2023
Q3 | $3.12K | Buy |
2,974
+2,860
| +2,509% | +$37.8K | ﹤0.01% | 2685 |
|
|
2023
Q2 | $1.29K | Hold |
114
| – | – | ﹤0.01% | 3014 |
|
|
2023
Q1 | $28.6K | Hold |
114
| – | – | ﹤0.01% | 1855 |
|
|
2022
Q4 | $29K | Hold |
114
| – | – | ﹤0.01% | 2633 |
|
|
2022
Q3 | $29K | Hold |
114
| – | – | ﹤0.01% | 2803 |
|
|
2022
Q2 | $29K | Hold |
114
| – | – | ﹤0.01% | 2559 |
|
|
2022
Q1 | $29K | Sell |
114
-5
| -4% | -$420 | ﹤0.01% | 2558 |
|
|
2021
Q4 | $14K | Hold |
119
| – | – | ﹤0.01% | 2103 |
|
|
2021
Q3 | $24K | Sell |
119
-40
| -25% | -$7K | ﹤0.01% | 1911 |
|
|
2021
Q2 | $27K | Buy |
159
+20
| +14% | +$3.63K | ﹤0.01% | 1799 |
|
|
2021
Q1 | $28K | Buy |
139
+40
| +40% | +$7.67K | ﹤0.01% | 1703 |
|
|
2020
Q4 | $20K | Hold |
99
| – | – | ﹤0.01% | 1809 |
|
|
2020
Q3 | $18K | Hold |
99
| – | – | ﹤0.01% | 1691 |
|
|
2020
Q2 | $23K | Sell |
99
-20
| -17% | -$3.81K | ﹤0.01% | 1518 |
|
|
2020
Q1 | $16K | Buy |
119
+20
| +20% | +$3.4K | ﹤0.01% | 1581 |
|
|
2019
Q4 | $20K | Hold |
99
| – | – | ﹤0.01% | 1619 |
|
|
2019
Q3 | $19K | Buy |
+99
| New | +$19.3K | ﹤0.01% | 1794 |
|
|
2019
Q1 | – | Sell |
-5
| Closed | -$1K | – | 3321 |
|
|
2018
Q4 | $1K | Buy |
+5
| New | +$1.06K | ﹤0.01% | 3381 |
|
|
2018
Q3 | – | Sell |
-20
| Closed | -$5K | – | 4016 |
|
|
2018
Q2 | $5K | Hold |
20
| – | – | ﹤0.01% | 3284 |
|
|
2018
Q1 | $3K | Hold |
20
| – | – | ﹤0.01% | 3409 |
|
|
2017
Q4 | $3K | Sell |
20
-94
| -82% | -$11.5K | ﹤0.01% | 3459 |
|
|
2017
Q3 | $14K | Hold |
114
| – | – | ﹤0.01% | 2844 |
|
|
2017
Q2 | $11K | Hold |
114
| – | – | ﹤0.01% | 2959 |
|
|
2017
Q1 | $21K | Hold |
114
| – | – | ﹤0.01% | 2483 |
|
|
2016
Q4 | $12K | Hold |
114
| – | – | ﹤0.01% | 2804 |
|
|
2016
Q3 | $18K | Buy |
+114
| New | +$15.9K | ﹤0.01% | 2475 |
|
Other funds holding SYRE
PA
RI
PBA
VA
DCM
IFP Advisors's SYRE Position: Q2 2026 in Review
IFP Advisors held its Spyre Therapeutics (SYRE) position steady in Q2 2026 at 24 shares worth $2.13K. The position accounts for ﹤0.01% of the portfolio, ranked #4207.
IFP Advisors first reported a position in SYRE in Q3 2016 and has held it in 37 quarters since. The position peaked at $29K in Q4 2022. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.
- IFP Advisors held 24 shares of Spyre Therapeutics worth $2.13K as of Q2 2026.
- IFP Advisors left its Spyre Therapeutics share count unchanged in Q2 2026.
- Spyre Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4207 holding.
- IFP Advisors first reported a position in Spyre Therapeutics in Q3 2016 and has held it in 37 quarters since.
- IFP Advisors's Spyre Therapeutics position peaked at $29K in Q4 2022.
- 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.